Warning: main(/home/corante/public_html/pipeline/includes/header.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/date_index.php on line 1

Warning: main(/home/corante/public_html/pipeline/includes/header.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/date_index.php on line 1

Warning: main() [function.include]: Failed opening '/home/corante/public_html/pipeline/includes/header.html' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/corante/public_html/pipeline/archives/date_index.php on line 1
About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily

In the Pipeline

Date Index
August 2014
29: A Last Summer Day Off
28: The Early FDA
28: Drug Repurposing
27: The Smallest Drugs
27: Life Is Too Short For Some Journal Feeds
26: A New Look at Phenotypic Screening
25: Small Molecules - Really, Really Small
25: InterMune Bought
25: Citable Garbage
22: The Palbociclib Saga: Or Why We Need a Lot of Drug Companies
21: Why Not Bromine?
21: Fragonomics, Eh?
20: Amicus Fights Its Way Through in Fabry's
20: Did Pfizer Cut Back Some of Its Best Compounds?
19: Don't Optimize Your Plasma Protein Binding
19: Fluorinated Fingerprinting
18: One of Those Days
18: ChemDraw Days
15: Incomprehensible Drug Prices? Think Again.
14: Proteins Grazing Against Proteins
13: Sulfates, And What They Can Make
13: Decorating Heterocycles Via Sulfinates
12: Rule of Ten?
12: Sulfur Fluoride Exchange
11: Med-Chem and Trucking, Together At Last
11: Is The Current Patent System Distorting Cancer Research?
08: Mouse Models of Inflammation: Wrong Or Not?
07: The Synthesis Machine
04: Summer Blogging Continues
04: Animal Testing in the UK.

July 2014
30: Amgen Cuts Hard
30: Abandoned Pharma
28: Targacept Comes Up Empty, Yet Again
28: Summer Blogging
25: The Antibiotic Gap: It's All of the Above
24: Phenotypic Assays in Cancer Drug Discovery
23: Neratinib Comes Through For Puma
23: How Many Biopharma Employees Would Rather Be Working Somewhere Else?
22: The Broad Gets $650 Million For Psychiatric Research
22: Put Them in Cells and Find Out
21: The Hep C Field Gets Nastier By the Minute
21: Allergan Twists and Turns
18: Chemistry Class For the "Food Babe"?
18: Thalidomide, Bound to Its Target
17: TDP-43 and Alzheimer's
17: Reversal of Type II Diabetes May Be Possible
16: An Easy Way to Make Cyclic Peptides
16: What Structures Have Turned on You?
15: K. C. Nicolaou on Drug Discovery
15: The Prospects of an Academic Job
14: Targacept Fumbles the Bad News on Alzheimer's
14: Modifying Red Blood Cells As Carriers
14: How to Run a Drug Project: Are There Any Rules at All?
11: Employment Among New Chemistry PhDs
11: My Imaginary Friends Would Be Glad to Serve as Referees
10: Biopharma Stock Events for the Rest of the Year
10: A Drug Candidate from NCATS
09: No Scripps/USC
09: Studies Show? Not So Fast.
09: Outsourced Assays, Now a Cause For Wonder?
08: An Alzheimer's Blood Test? Not So Fast.
08: AbbVie and Shire, Quietly
07: Catalyst Voodoo, Yielding to Spectroscopy?
07: That Retracted Stressed Stem Cell Work
04: Happy Fourth of July, 2014
03: An Early Day Off
02: All Natural And Chemical Free
01: Scientific Journals: Who Pays What?
01: Corrosion Using Selectfluor?
01: Chemical-Free Products: The Complete List

June 2014
30: The GSK-China Situation Gets Even Weirder
30: Don't Learn to Science?
27: Varieties of Scientific Deception
26: Absence Makes the Ideas Flow?
26: Alzheimer's Bonds
25: Where's the Widest Variety of Chemical Matter?
25: That's Just Too Colorful
25: Zafgen's Epoxide Pays Its Way
24: Taking Risks - You Have To, So Do It Right
24: Whooo-eee
23: Go Home, Gaijin
23: The Virtual Clinical Trial: Not Quite Around the Corner
23: Stephanie Kwolek, 1923-2014
21: Scripps Update
20: What If Drug Patents Were Written Like Software Patents?
20: Stem Cells: The Center of "Right to Try"
19: Speaking of Polyphenols. . .
19: Dark Biology And Small Molecules
18: How Polyphenols Work, Perhaps?
18: More On Automated Medicinal Chemistry
17: Scripps Merging With USC?
16: Your Metal Azide Worries Are Over
16: A "Right to Try" Debate
13: Med-Chem, Automated?
13: Rearrangements Inside Bristol-Myers Squibb
13: "In the Pipeline" Will Be Moving
12: Valeant's Misleading Case
12: Amylin Fibrils and Aspirin: No Connection
12: Nutley Demolished
11: Valuing Biotech Startups
11: Whack-A-Mole
10: Right To Try: Here We Go
09: Hosed-Up X-Ray Structures: A Big Problem
09: Good News! Our Alzheimer's Drug Didn't Work!
06: Sanofi's Feeling Just Wonderful
06: The Robustness Test: Why Don't We Just Require It?
05: Friendly, Welcoming Triazides. No, Really.
05: Get the Science Out of Your Yogurt
04: Pharmalot Returns
04: Predicting New Targets - Another Approach
03: Alex Shulgin, 1925-2014
02: More Server Problems
02: Single-Cell Compound Measurements - Now In A Real Animal
02: No More Acid Stem Cells

May 2014
30: A New Med-Chem Reference
30: Covalent Fragments
29: How to Buy, Buy, Buy
29: The Price of Sovaldi
28: The Science Chemogenomics Paper is Revised
28: Would You Have Advanced BBI608?
27: Mix-and-Match Natural Products
27: AstraZeneca Survives
23: I'll have the Cesium Cole Slaw and the Francium Fries, Too
23: Two Looks At Drug Industry Productivity
22: The Biggest Chemistry Employers - Guess
22: Oncoceutics' Odd Press Releases (Spam Never Sleeps)
22: A Horrible, Expensive, and Completely Avoidable Drug Development Mixup
21: Hit the Polyamine Pedal, And Hold It
21: Pfizer/AstraZeneca: The Arm-Wrestling Phase
21: This All Too Open Office
20: Perhaps Not Quite Technically Legal, Come to Think of It
20: Xenon's Use as a Sports Drug Is Banned
20: Where the Talent Comes From
19: AstraZeneca Looks At Its Own History, And Cringes
19: AstraZeneca Says No Again
16: Photochemical Reaction Discovery
16: The Real Numbers on Tamiflu
15: Citalopram for Alzheimer's?
15: The Daily Show on Finding New Antibiotics
14: A Unique Correction
14: China Raises the Stakes in the GSK Scandal
14: Google Honors Dorothy Hodgkin and Percy Julian
13: How Many Elements Have You Used, As Elements?
13: Fluorination, The Old-Fashioned Way
13: A Ligand Efficiency Reply
12: Pfizer's Shareholders and AstraZeneca's
12: For A Science Center, This Is a Disgrace
12: DMSO Will Ruin Your Platinum Drugs. Take Heed.
12: Photoredox Marches On
09: Watching A Palladium Reaction, In A Crystalline Flask
08: Alzheimer's Antibodies: Can the Current Ones Even Work?
08: Oh Brave New World
08: Artificial Base Pairs in Living Cells
07: Pfizer-AZ: Politics and Press Releases
07: Crap, With the Force of Law Behind It
07: The Lessons of Intercept and NASH
06: AstraZeneca: Don't Buy Us
06: CRISPR In the Courts
06: Telling the Truth
06: Technical Problems
05: Fast Money, But What Direction Is It Going?
05: Pfizer/AstraZeneca: Asymmetric Cuts Look Likely
05: Young Blood
02: Some People at Pfizer Whose Fault This Isn't
02: Allergan: "Golf-Course Deprived"
02: AstraZeneca Tell Pfizer to Buzz Off
01: Can Anything Stop Pfizer-AstraZeneca From Going Through?
01: Another Whack at the Cost of Drugs Issue
01: Merrimack Wins One
01: Eli Lilly vs. Canada

April 2014
30: Back Ordered, I'll Bet
30: Is That Food or Not?
29: Mice Hate Men
29: Concert's First Drug: Not So Great
28: Pfizer and AstraZeneca: What the Hell.
25: Ycombinator Gets Into Biotech
22: Days Off
22: Shuffling the Departments
22: Funding Undergraduate Summer Research
22: J. Appl. Drivel or Gibberish Lett.? Choices, Choices.
21: Molecular Printing of Drug Molecules. Say What?
21: Pfizer Walks Again By Night
17: Gitcher SF5 Groups Right Here
17: Changing A Broken Science System
16: One and Done
16: The Latest Protein-Protein Compounds
16: Professor Fukuyama's Solvent Peaks
15: Novartis Gets Out of RNAi
15: Total Synthesis in Flow
15: Sweet Reason Lands On Its Face
14: More on the Science Chemogenomic Signatures Paper
11: Biology Maybe Right, Chemistry Ridiculously Wrong
10: Encoded Libraries Versus a Protein-Protein Interaction
09: The State of Alzheimer's Research, 2014
09: AstraZeneca's Cambridge Move
08: A Call For Better Mouse Studies
08: Biotech Boom, Biotech Bust?
08: Can You Patent A Natural Product? Prepare For a Different Answer
07: Is Palbociclib Promising? Or Not?
07: Outsourcing Everything
07: Cancer Immunotherapy's Growing Pains
04: GSK Dismisses Employees in Bribery Scandal. Apparently.
04: Ancient Modeling
03: More Fukuyama Corrections
03: Reality-Based Biotech Investing
02: Binding Assays, Inside the Actual Cells
01: Freeman Dyson on the PhD Degree
01: Off To the Publishers
01: Yeah, That Must Be It

March 2014
31: Where The Hot Drugs Come From: Somewhere Else
31: A Quick Clean-Up
28: More on the UT-Austin Retraction Case
28: A Huntington's Breakthrough?
27: A Look Back at Big Pharma Stocks
27: Another Target Validation Effort
27: Dichloroacetic Acid, In a New Form
26: A New Fluorination
26: Getcher Nucleic Acids, Cheap
25: A New Way to Study Hepatotoxicity
24: Google's Big Data Flu Flop
24: Nitrogen Heterocycles Ahoy
24: Ezetimibe In the Marketplace
21: Dosing by Body Surface Area
21: Another Use for Xenon
20: For Some Folks, It's New Year's Day
20: Small Molecule Chemistry's "Limited Utility"?
20: Years Worth of the Stuff
19: Another Whack at the Stem Shortage Myth
19: More Things Synthetic Chemists Hate
18: Another DNA-Barcoded Program From GSK
18: Jailhouse Secrets They Don't Want You to Know About!
17: What If Total Syntheses Had Only 25 Steps to Work In?
17: Predicting What Group to Put On Next
14: Going After Poor Published Research
14: The Genetics of Bipolar Disorder: What A Tangle
14: A Sirtuin Activator Extends Lifespan in Normal Mice
13: The Reasons for Failure at the FDA
12: A New NMR Probe Technology in the Making?
12: Stem Cell Shakedown Cruise
11: Compassionate Use: An Especially Tough Case
11: Always Insist on Error Bars
10: Startups vs. Big Pharma
10: A Blood Test for Alzheimer's?
10: Repurposing for Cervical Cancer
07: Some New Reviews
07: A Structure From the Molecular Sponge
06: Biggest US Cities for Biopharma Funding, Versus Whole Continents.
06: We Are Pleased To Publish Your Senseless Ravings
05: Traveling Interruption
04: More Good PD-1 News in Cancer
04: Novartis's Stealthy Headcount Reductions
03: Sydney Brenner on the State of Science
03: A Bit More Realism in Consulting
03: Out to Illinois

February 2014
28: A Call To Rein In Phase III Trials
28: Computational Nirvana
27: A Close Look at Receptor Signaling
26: The Instructive Case of Galena Biopharma
26: Changes in Papers
25: InterMune Comes Through
25: For Immediate Rewording. Uh, Release.
24: ACS Webinars on Drug Discovery
24: Big Drug Mergers: So They're OK, Right?
24: Another Round of Stapled Peptide Wrangling
21: Ces3 (Ces1) Inhibition As a Drug Target
21: Making Arenes React, Via Rhodium
20: The NIH Takes a Look At How the Money's Spent
20: Pfizer Seeks Respect
19: Robo-Combing the Chemistry Literature For Mistakes
19: Ligand Efficiency: A Response to Shultz
18: Thoughts on Overpublishing
18: Not Again - Stem Cell Results in Trouble?
17: The Org Lett Spectral Hammer Falls Again
17: Down With P Values
17: Alan Katritzky 1928-2014
14: "It Is Not Hard to Peddle Incoherent Math to Biologists"
13: Jobs, He Says
12: The Bread Rolls of Synthesis
12: Genius, Sheer Genius
11: Drug Discovery in India
11: Pesticide Toxicity?
10: How the New BioPharma IPOs Have Been Doing
10: Today We Have Naming of Parts
10: A Timeline from Cell
07: Irisin and Metabolism - A New Target Emerges
07: Thermodynamics of Life
06: Crowdfunding Independent Research
06: On Vitamin C, And On Linus Pauling
06: AstraZeneca Cutting Back - Some More
05: More Ligand Efficiency
05: The Evidence Piles Up: Antioxidant Supplements Are Bad For You
04: Put Down That White-Out; Drop That Photoshop Cursor
04: Overqualified For the Job
03: A New Book
03: Novartis Does A Big, Quiet Reshuffle
03: The Return of Gene Therapy (And More)

January 2014
31: "The Time Had Now Come to Attempt the First Large-Scale Reaction. . ."
31: How Not to Invest in Biopharma
31: Beelzebub Pharma, Inc.
30: The West Virginia Formaldehyde Claim Is Nonsense
29: AstraZeneca Closes a Lab - In India This Time
29: What STEM Shortage? Where? How?
28: Antivirals: "I Love the Deviousness of It All"
28: Dacomitinib Doesn't Come Through
27: The 2013 Crop of New Drugs
27: The Nasty Side of HDL
24: PTC's Latest Ataluren Woes
24: Are There Good Writers In This Business?
23: Clicked-DNA Works In Human Cells
23: Alzheimer's Therapies: A Reasonably Gloomy Update